- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Lilly names Pennsylvania site for its latest US facility | ||
| 30.01. | EMA looks into 'data integrity' issue with Amgen's Tavneos | ||
| 30.01. | FDA starts review of Summit's VEGFxPD-1 bispecific | ||
| 30.01. | Three more biotechs price their Nasdaq IPOs | ||
| 30.01. | GLP-1 drugs linked to pancreatitis, gallbladder problems | ||
| 30.01. | AstraZeneca deepens Chinese ties, signs $18.5bn CSPC Pharma obesity deal | ||
| 29.01. | Tenpoint eyes presbyopia drug launch after FDA nod | ||
| 29.01. | Digital musculoskeletal care firm Sword buys rival Kaia | ||
| 29.01. | Otsuka preps for July decision on centanafadine for ADHD | ||
| 28.01. | Halozyme diversifies in drug delivery with Surf Bio buy | ||
| 28.01. | Eikon prices its IPO, seeking to raise $318m | ||
| 28.01. | Lilly allies with gene-editing firm Seamless on hearing loss | ||
| 28.01. | Boehringer drug scores in rare kidney disease FSGS | ||
| 28.01. | CMS's Medicare price negotiations start round three | ||
| 28.01. | UK biotech sees "strong finish" to 2025 financing | ||
| 28.01. | Introducing the Sunday Times Tech 100: Life sciences part 3 | ||
| 27.01. | China clears its first drug for chronic hepatitis D | ||
| 27.01. | Boehringer signs €1bn+ deal for Simcere IBD candidate | ||
| 27.01. | Roche claims midstage win for obesity injectable | ||
| 27.01. | Vaccination fall costs UK its measles elimination status | ||
| 27.01. | Introducing the Sunday Times Tech 100: Life sciences part 2 | ||
| 26.01. | Bausch Health hit as Xifaxan successor flunks trials | ||
| 26.01. | MSD said to have pulled back from Revolution Medicines deal | ||
| 26.01. | COPD patients will get access to Dupixent via NHS | ||
| 26.01. | Introducing the Sunday Times Tech 100: Life sciences part 1 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.